The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, registrational-intent, multicenter Phase 2b trial of ACR-368 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback